Nature:破解寨卡病毒秘密!解析寨卡病毒结构并鉴定药物靶向位点

2016-04-21 生物谷 生物谷

在一项新的研究中,来自杜克-新加坡国立大学医学院(Duke-NUS)的研究人员在理解寨卡病毒(ZIKV)结构方面取得重要突破。相关研究结果于2016年4月19日在线发表在Nature期刊上,论文标题为“Structure of the thermally stable Zika virus”。 这些发现揭示出ZIKV病毒结构,并且鉴定出这种病毒表面上的潜在药物靶向作用位点。这一认识将有助

在一项新的研究中,来自杜克-新加坡国立大学医学院(Duke-NUS)的研究人员在理解寨卡病毒(ZIKV)结构方面取得重要突破。相关研究结果于2016年4月19日在线发表在Nature期刊上,论文标题为“Structure of the thermally stable Zika virus”。

这些发现揭示出ZIKV病毒结构,并且鉴定出这种病毒表面上的潜在药物靶向作用位点。这一认识将有助全世界努力抵抗这种知之甚少的病毒。当前,ZIKV是公共卫生和研究的重点。

Duke-NUS副教授Shee-Mei Lok和她的研究团队利用低温电子显微技术分析大量纯化的ZIKV病毒颗粒,并且捕获这种病毒的图片。通过使用上千张图片,他们重建出ZIKV的高分辨率低温电子显微结构。(进一步阅读:Science:首次解析出寨卡病毒三维结构

这种高分辨率结构表明这个病毒的整体结构类似于其他的黄病毒科病毒,如西尼罗病毒和登革热病毒。然而,研究人员发现ZIKV要比登革热病毒具有更大的热稳定性,而且即便在40℃---模拟在ZIKV感染后高烧患者的体温---下孵育时,在结构上也是稳定的。

这种结构也揭示出相比于登革热病毒,ZIKV表面蛋白具有更紧密的相互作用,因此使得它比登革热病毒更加稳定。这或许可以解释它能够在诸如精子、唾液和尿液之类的严峻环境中存活下来。除了通过被感染的蚊子叮咬进行传播外,这种病毒的结构稳定性使得它具有更强的适应性,这可能解释它具有通过性接触进行传播的特殊能力。类似的病毒,如西尼罗病毒和登革热病毒,不能够通过性接触进行传播。

总体而言,这些发现提示着让ZIKV结构去稳定化的抗体或药物可能有助降低这种病毒传染病的严重性,或者限制它的扩散。

Lok说,“这是令人兴奋的,这是因为我们的结构将给世界各地正在努力发现抵抗ZIKV的治疗试剂的其他研究人员提供重要线索。”

“此外,我们已证实ZIKV具有不同于来自同一个病毒科的影响大脑的其他病毒(如西尼罗病毒)的独特结构,而且也具有不同于导致发热的那些病毒(如登革热病毒)的独特结构。能够让这些结构发生突变以便更好地理解它们如何影响ZIKV感染人类,而且也能够潜在地导致人们开发出一种安全的降低这些副作用的疫苗。”

Lok的下一步就是理解强效抗体对ZIKV的影响。通过研究这项研究中提供的结构,她的团队将努力确定这些抗体如何可能被用来杀死这种病毒。他们也希望鉴定出哪些强效抗体可能能够在紧急情况下用于治疗病人,如ZIKV传染病突然暴发或者妊娠期间感染ZIKV的情形下。

ZIKV导致寨卡病毒病,其常见症状为轻度发烧、皮疹、结膜炎、肌肉和关节疼痛、虚弱或头疼。

今年2月,世界卫生组织宣布寨卡病毒传播是“一种引起国际关注的公共卫生紧急事态”。科学家们已发现这种病毒与胎儿小头畸形(microcephaly)和成年人格林-巴利综合征(Guillain-Barré syndrome)相关联。

原始出处:

Victor A. Kostyuchenko, Elisa X. Y. Lim, Shuijun Zhang,et al,Structure of the thermally stable Zika virus,Nature,2016 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1672778, encodeId=423216e2778f9, content=<a href='/topic/show?id=b79b910345c' target=_blank style='color:#2F92EE;'>#解析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91034, encryptionId=b79b910345c, topicName=解析)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f42d26916490, createdName=hongbochen, createdTime=Tue Jul 19 15:51:00 CST 2016, time=2016-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880998, encodeId=7a251880998a5, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Mon Feb 06 07:51:00 CST 2017, time=2017-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1811373, encodeId=c22818113e373, content=<a href='/topic/show?id=38628e90472' target=_blank style='color:#2F92EE;'>#药物靶向#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87904, encryptionId=38628e90472, topicName=药物靶向)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=198d2500149, createdName=12498bd5m16暂无昵称, createdTime=Tue Aug 02 20:51:00 CST 2016, time=2016-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1359997, encodeId=ad2b135999e92, content=<a href='/topic/show?id=6783466083f' target=_blank style='color:#2F92EE;'>#寨卡病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46608, encryptionId=6783466083f, topicName=寨卡病毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sat Apr 23 01:51:00 CST 2016, time=2016-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1512819, encodeId=a2a2151281903, content=<a href='/topic/show?id=f0364660360' target=_blank style='color:#2F92EE;'>#寨卡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46603, encryptionId=f0364660360, topicName=寨卡)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d79610514526, createdName=12498710m14暂无昵称, createdTime=Sat Apr 23 01:51:00 CST 2016, time=2016-04-23, status=1, ipAttribution=)]
    2016-07-19 hongbochen
  2. [GetPortalCommentsPageByObjectIdResponse(id=1672778, encodeId=423216e2778f9, content=<a href='/topic/show?id=b79b910345c' target=_blank style='color:#2F92EE;'>#解析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91034, encryptionId=b79b910345c, topicName=解析)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f42d26916490, createdName=hongbochen, createdTime=Tue Jul 19 15:51:00 CST 2016, time=2016-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880998, encodeId=7a251880998a5, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Mon Feb 06 07:51:00 CST 2017, time=2017-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1811373, encodeId=c22818113e373, content=<a href='/topic/show?id=38628e90472' target=_blank style='color:#2F92EE;'>#药物靶向#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87904, encryptionId=38628e90472, topicName=药物靶向)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=198d2500149, createdName=12498bd5m16暂无昵称, createdTime=Tue Aug 02 20:51:00 CST 2016, time=2016-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1359997, encodeId=ad2b135999e92, content=<a href='/topic/show?id=6783466083f' target=_blank style='color:#2F92EE;'>#寨卡病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46608, encryptionId=6783466083f, topicName=寨卡病毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sat Apr 23 01:51:00 CST 2016, time=2016-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1512819, encodeId=a2a2151281903, content=<a href='/topic/show?id=f0364660360' target=_blank style='color:#2F92EE;'>#寨卡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46603, encryptionId=f0364660360, topicName=寨卡)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d79610514526, createdName=12498710m14暂无昵称, createdTime=Sat Apr 23 01:51:00 CST 2016, time=2016-04-23, status=1, ipAttribution=)]
    2017-02-06 liye789132251
  3. [GetPortalCommentsPageByObjectIdResponse(id=1672778, encodeId=423216e2778f9, content=<a href='/topic/show?id=b79b910345c' target=_blank style='color:#2F92EE;'>#解析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91034, encryptionId=b79b910345c, topicName=解析)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f42d26916490, createdName=hongbochen, createdTime=Tue Jul 19 15:51:00 CST 2016, time=2016-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880998, encodeId=7a251880998a5, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Mon Feb 06 07:51:00 CST 2017, time=2017-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1811373, encodeId=c22818113e373, content=<a href='/topic/show?id=38628e90472' target=_blank style='color:#2F92EE;'>#药物靶向#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87904, encryptionId=38628e90472, topicName=药物靶向)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=198d2500149, createdName=12498bd5m16暂无昵称, createdTime=Tue Aug 02 20:51:00 CST 2016, time=2016-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1359997, encodeId=ad2b135999e92, content=<a href='/topic/show?id=6783466083f' target=_blank style='color:#2F92EE;'>#寨卡病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46608, encryptionId=6783466083f, topicName=寨卡病毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sat Apr 23 01:51:00 CST 2016, time=2016-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1512819, encodeId=a2a2151281903, content=<a href='/topic/show?id=f0364660360' target=_blank style='color:#2F92EE;'>#寨卡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46603, encryptionId=f0364660360, topicName=寨卡)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d79610514526, createdName=12498710m14暂无昵称, createdTime=Sat Apr 23 01:51:00 CST 2016, time=2016-04-23, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1672778, encodeId=423216e2778f9, content=<a href='/topic/show?id=b79b910345c' target=_blank style='color:#2F92EE;'>#解析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91034, encryptionId=b79b910345c, topicName=解析)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f42d26916490, createdName=hongbochen, createdTime=Tue Jul 19 15:51:00 CST 2016, time=2016-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880998, encodeId=7a251880998a5, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Mon Feb 06 07:51:00 CST 2017, time=2017-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1811373, encodeId=c22818113e373, content=<a href='/topic/show?id=38628e90472' target=_blank style='color:#2F92EE;'>#药物靶向#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87904, encryptionId=38628e90472, topicName=药物靶向)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=198d2500149, createdName=12498bd5m16暂无昵称, createdTime=Tue Aug 02 20:51:00 CST 2016, time=2016-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1359997, encodeId=ad2b135999e92, content=<a href='/topic/show?id=6783466083f' target=_blank style='color:#2F92EE;'>#寨卡病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46608, encryptionId=6783466083f, topicName=寨卡病毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sat Apr 23 01:51:00 CST 2016, time=2016-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1512819, encodeId=a2a2151281903, content=<a href='/topic/show?id=f0364660360' target=_blank style='color:#2F92EE;'>#寨卡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46603, encryptionId=f0364660360, topicName=寨卡)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d79610514526, createdName=12498710m14暂无昵称, createdTime=Sat Apr 23 01:51:00 CST 2016, time=2016-04-23, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1672778, encodeId=423216e2778f9, content=<a href='/topic/show?id=b79b910345c' target=_blank style='color:#2F92EE;'>#解析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91034, encryptionId=b79b910345c, topicName=解析)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f42d26916490, createdName=hongbochen, createdTime=Tue Jul 19 15:51:00 CST 2016, time=2016-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880998, encodeId=7a251880998a5, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Mon Feb 06 07:51:00 CST 2017, time=2017-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1811373, encodeId=c22818113e373, content=<a href='/topic/show?id=38628e90472' target=_blank style='color:#2F92EE;'>#药物靶向#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87904, encryptionId=38628e90472, topicName=药物靶向)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=198d2500149, createdName=12498bd5m16暂无昵称, createdTime=Tue Aug 02 20:51:00 CST 2016, time=2016-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1359997, encodeId=ad2b135999e92, content=<a href='/topic/show?id=6783466083f' target=_blank style='color:#2F92EE;'>#寨卡病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46608, encryptionId=6783466083f, topicName=寨卡病毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sat Apr 23 01:51:00 CST 2016, time=2016-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1512819, encodeId=a2a2151281903, content=<a href='/topic/show?id=f0364660360' target=_blank style='color:#2F92EE;'>#寨卡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46603, encryptionId=f0364660360, topicName=寨卡)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d79610514526, createdName=12498710m14暂无昵称, createdTime=Sat Apr 23 01:51:00 CST 2016, time=2016-04-23, status=1, ipAttribution=)]

相关资讯

中科院武汉病毒所等成功分离出寨卡病毒

中科院武汉病毒所近期与深圳出入境检验检疫局合作,成功分离出1株寨卡病毒。该株病毒和解放军军事医学科学院首次分离的SZ01株寨卡病毒属于同一血清样本,都来源于从萨摩亚入境我国深圳的患者。武汉病毒所副所长肖庚富研究员从深圳出入境检验检疫局获得最后50微升珍贵血清样本;该所黄病毒课题组研究员张波带领团队克服了血清量少的困难,通过接种C6/36蚊子细胞,经过3次传代成功分离得到病毒,并利用寨卡病毒特异性引

赛默飞助力完成两例寨卡病毒全基因组序列测定

上海——科学服务领域的世界领导者赛默飞世尔科技(以下简称:赛默飞)近日凭借Ion Torrent半导体测序平台在高通量测序上的领先技术和卓越性能,先后帮助中国疾控中心和解放军军事科技院从血液和尿液中成功获得寨卡病毒全基因组序列。这两例病毒全基因组序列的测定为寨卡病毒的溯源和进化提供了重要证据;同时对于后续诊断试剂、药物和疫苗的研发具有深刻意义。 “从先前的H1N1禽流感、埃博拉,到现在的寨卡疫情

世卫组织:已有36国报告寨卡病毒确诊病例

世界卫生组织19日称,已有36国报告寨卡病毒确诊病例。世卫组织总干事陈冯富珍对中国方面采取的有关防控措施予以肯定。 世卫组织当天发表最新寨卡病毒疫情通报说,寨卡病毒已在28个美洲国家和地区出现本地传播。巴西等地的小头症病例激增。除小头症外,寨卡病毒传播与格林-巴利综合征病例增加之间的联系也引起关注。巴西等多个拉美国家报告格林-巴利综合征发病率上升。 世卫官员表示,截至1月底,巴西共报告近480

Lancet:塞卡病毒感染引发神经系统异常

(图片摘自www.sciencealert.com) 目前绝大部分媒体对美国境内塞卡病毒流行趋势的报道都集中在其与"小头病"(即导致新生儿头骨与脑部畸形的一种神经异常疾病)的关系上。然而塞卡病毒被认为与Guillain-Barré综合征(GBS),即一类罕见但是也十分严重的神经疾病(有时会导致暂时性的麻痹,或可致死)也具有一定的联系。 最近一项新的研究证明塞卡病毒可能会导致GBS的发生。

Cell Stem Cell:华人夫妇揭示寨卡病毒导致小头症的秘密,破坏神经干细胞

最新研究显示,寨卡病毒能感染并杀死对大脑发育至关重要的神经干细胞。这是科学家第一次发现寨卡病毒与新生儿小头症之间有生理关联的证据,有助于医学界更有针对性地探索对抗寨卡的治疗方法。在美国工作的华人科学家美国约翰斯·霍普金斯大学的明囯丽、宋红军、佛罗里达州立大学的唐恒立以及埃默里大学的金鹏带领四个研究小组联合攻关,从2月初开始连续工作约一个月后得到上述发现。鉴于寨卡病毒研究的重要性,他们的论文仅用一周

巴西奥运会门票还真卖不出去了?!

四年一度的全球体育盛会还剩下110多天就要在巴西里约热内卢举行啦,遥想08年北京奥运会的盛况,心情仍十分激动,虽然遗憾没能到现场参观,但看电视这场景也是很震撼了!这人山人海,这气势磅礴!我激动!我骄傲!但2016年里约热内卢奥运会主办方,现在不是愁着交通,场地设置,环境,而是愁着门票卖不出去啊!4月5日里约奥运组委会发言人菲尔·威尔金森(Phil Wikinson)在接受媒体采访时表示,目前为止奥